This is an author version of the contribution published on:

The definitive version is available at:
http://link.springer.com/article/10.1007/s00280-014-2381-4
Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients

Paola Milla, Chiara Fiorito*, Francesco Soria*, Silvia Arpicco, Luigi Cattel, Paolo Gontero*

Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, and *Urologia 1, University of Turin

E-mail address:
Paola Milla: paola.milla@unito.it
Chiara Fiorito: chiara@mailbox19.net
Francesco Soria: soria.fra@gmail.com
Silvia Arpicco: silvia.arpicco@unito.it
Luigi Cattel: luigi.cattel@unito.it
Paolo Gontero: paolo.gontero@unito.it

Corresponding author:
Paola Milla
Dipartimento di Scienza e Tecnologia del Farmaco
Corso Raffaello 31
10125 Torino (Italy)
e-mail: paola.milla@unito.it
ABSTRACT

Purpose
To evaluate, for the first time, the mitomycin C (MMC) pharmacokinetics during intravesical hyperthermia treatment based on conductive heat and the stability and recovery of the drug at the end of the instillation period.

Methods
Eleven patients with recurrent intermediate risk superficial transitional cell carcinoma of the bladder were treated weekly for 6 cycles with intravesical MMC (40 mg MMC in 50 ml) in local hyperthermia (45°C) with Unithermia® system. Each instillation lasted 45 min, with the solution being replaced after the first 22 min. The MMC recovery at the end of the two instillation period and the plasmatic pharmacokinetics of MMC were evaluated by high-pressure liquid chromatography (HPLC).

Results
Nine patients completed all the 6 planned cycles, whereas 2 patients missed the last cycle because of allergic reactions. No other systemic toxicity was observed, the local toxicities were mild. Median MMC concentration in the instillation residual solution decrease from the initial 0.8 mg/ml to 0.22 mg/ml for the 0-22 min instillation period and to 0.38 mg/ml for the 22-45 min instillation period; the median % of MMC recovered after instillation was 66.2 and 99.6, respectively. In all patients MMC plasmatic $C_{\text{max}}$ resulted considerably lower than the toxic threshold (400 ng/ml).

Conclusions
The MMC is stable during the instillation and its absorption occurs mainly during the first minutes of the treatment. The plasmatic MMC concentration is always well below the threshold level for myelosuppression, as confirmed by the total lack of hematological toxicity evidenced by the patients. In order to evaluate the efficacy of the treatment performed with UniThermia® in reducing the disease recurrence rate in short- and long-term follow-up, we are currently carrying out a clinical multicentric study involving a larger number of patients.

KEYWORDS
Superficial transitional cell carcinoma, Mitomycin C, bladder hyperthermia, intravesical chemotherapy, pharmacokinetics.
Introduction

Superficial transitional cell carcinoma (TCC) of the bladder accounts for more than 90% of bladder cancers in developed countries. At diagnosis, 70-80% of TCC are superficial and can be classified as Ta (confined to the urothelium), T1 (invading the lamina propria) or CIS (carcinoma in situ, a highly aggressive type of superficial TCC). According to the World Health Organization (WHO) superficial TCC can be further classified as low grade (grade 1 and 2) or high grade (grade 3) [1].

The standard of treatment for patients with superficial TCC is surgical transurethral resection (TUR) of tumors, performed with the dual purpose to resect every visible tumor and to collect sample tissue for pathological examination. The further treatment of superficial TCC after TUR depends on the degree of risk of recurrence and progression of the tumor: low-risk TCC (small monofocal TaG1, still not relapsed) presents a low risk of recurrence and progression (20% recurrence at one year post-TUR) and can be successfully managed with endovesical chemotherapy standard protocols, whereas high-risk TCC (plurifocal T1G2, monofocal T1G3) presents a high risk of recurrence and progression (90% recurrence at one year post-TUR) and should be treated with endovesical instillation of the immunomodulating agent Bacille Calmette-Guérin (BCG). At the appearance of tumor multiple recurrences or progression after BCG treatment, the only remaining option is the radical cystectomy [2-4].

Recently, Elmedical has developed UniThermia©, a new system for the delivery of intravesical thermo-chemotherapy based on conductive heat. The UniThermia© system comprises a console (Pelvix™), a peristaltic pump and an heat exchanger, and it is able to deliver intravesical chemotherapy, with moderate heat (42-45°C) and high flow (whole bladder content replaced 5 times per minute), through a 3-way silicon catheter.

More recently, Elmedical has developed UniThermia®, a new system for the delivery of intravesical thermo-chemotherapy based on conductive heat. The UniThermia® system comprises a console (Pelvix™), a peristaltic pump and an heat exchanger, and it is able to deliver intravesical chemotherapy, with moderate heat (42-45°C) and high flow (whole bladder content replaced 5 times per minute), through a 3-way silicon catheter.

The aim of the study described in this paper was to evaluate, for the first time, the MMC pharmacokinetics during hyperthermia treatment performed with UniThermia®, and the stability and recovery of the drug from the residual bladder contents at the end of the instillation period.
Patients and methods

Chemicals
Mitomycin C (MMC) used as standard for the HPLC calibration curve, was from Sigma (Milan, Italy). Organic solvents (HPLC grade) were obtained from Carlo Erba (Milan, Italy). The MMC solution used for intravesical instillation was obtained from Kyowa Italiana Farmaceutici s.r.l. (Milan, Italy) and was freshly prepared in 0.9% saline prior to each treatment.

Equipments
The system used for intravesical thermo-chemotherapy was the Unithermia®, provided from Elmedical (Hod-Hasharon, Israel), and already approved for sale in the European market. Unithermia® is an office-based system composed of a compact console and catheters that allows to obtain an uniform hyperthermia all over the bladder by high flow of a heated MMC solution.

Patients
Eleven patients with recurrent stage Ta and T1, grade G1 or G2, TCC of the bladder were enrolled onto this study in the Department of Urology of San Giovanni Battista-Molinette Hospital of Turin, Italy. Patients were enrolled if affected by intermediate-risk, stage Ta and T1, grade G1 or G2, mono- or plurifocal (excepted plurifocal T1G2) TCC of the bladder, recurrent after almost a BCG complete cycle of treatment during the previous 24 month. Patients were included with a WHO performance status of 0-2 and an age ≤85 years. Before entering onto study, patients underwent complete TUR of all tumors, confirmed by a post-TUR cystoscopy, cold-cup biopsies of suspicious areas and negative urinary cytology. Exclusion criteria were the following: high-risk TCC (T1G3, CIS, multifocal T1G2, high grade cellular atypia) or invasive bladder cancer; transitional cell carcinoma of the prostatic urethra or bladder cancer different from TCC; bladder capacity < 150 mL or patient unable to hold the urine for at least 1 h; known allergy to MMC; WHO performance status 3-4; age > 85 years; WBC count < 3.000 cells/mm³ and/or platelets < 100.000 cells/mm³; renal and liver function > twice the upper normal limit; urinary tract infection unresponsive to treatment; no previous treatment with BCG; pregnancy or breast feeding. Before starting the experimental treatment, all patients were required to sign an informed consent form defined according to the Helsinki Committee and approved by the local Ethics Committee. Clinical and demographic characteristics of the patients are shown in Table 1.

Pre-treatment and follow-up evaluation
Before starting the treatment, patients underwent complete TUR of all tumors, histological examination of resected tissue, cold-cup biopsies of all suspicious areas, bimanual palpation, blood tests (complete hematological analysis, AST, ALT, LDH, γGT, urea, creatinine), urinalysis with uroculture and urinary cytology, kidney and bladder ultrasound examination, chest radiography and quality of life evaluation by EORTC QLQ-C30 and QLQ-BLS24 questionnaires.

Blood tests were repeated before each instillation and questionnaires were proposed again at the end of 6 cycles treatment and 1 year later.

Patients were monitored by kidney and bladder ultrasound examination after 6 and 12 months and by urinary cytology and cystoscopy every 3 months during the first year and then every 6 months. All lesions detected by cystoscopy were subjected to biopsy, and the recurrence was evaluated by histological examination. Patients with positive cytology without cystoscopically noticeable lesions were subjected to biopsies by a bladder mapping in order to evidence a possible CIS. Patients diagnosed with CIS were withdrawn from the study.

Treatment
Within 24 hours from TUR, patients were treated with intravesical MMC in local hyperthermia with Unithermia® system: a solution of 40 mg MMC in 50 ml 0.9% saline (concentration 0.8 mg/ml), heated at 45°C, was instilled in the bladder and maintained in continuous circulation for 22 minutes, then the bladder was emptied and infused with fresh MMC solution at the same dosage and temperature for a second 23 min period. The same treatment was repeated weekly for a total number of 6 cycles.

Sampling
The MMC recovery at the end of the two instillation periods was evaluated for all the 11 patients in all the instillation cycles, whereas the plasmatic pharmacokinetics of MMC was evaluated during the third cycle for 7 patients. The volume and pH of the solution recovered from the bladder were measured after both the first 22-min (when the bladder was emptied and the drug solution replaced with a fresh one) and the second 23-min instillation period. Aliquots were stored immediately at –80°C until analysis.

Blood samples were collected in heparinized tubes immediately before instillation and at 11, 22 (time of replacing the MMC solution), 45 (time of voiding), 75 and 105 min. Plasma was immediately separated by centrifugation and stored at –80°C until analysis.

Sample preparation
Frozen aliquots of the solution recovered from the bladder were thawed, vortexed for 10 s and centrifuged for 5 min at 15800xg and 4°C, then 20 μl were diluted 1:2000 in HPLC mobile phase (0.01 M NaH₂PO₄ buffer pH 6.5/acetonitrile, 84:16) immediately
before the HPLC analysis. MMC was extracted from plasma samples as described by Joseph et al. with minimal modification [23]. Briefly, frozen aliquots of plasma were thawed and vortexed for 10 s, 1 ml of plasma was transferred into a centrifuge tube and 1 ml of acetonitrile was added for protein precipitation and MMC extraction. The tube was vortexed for 1 min and centrifuged for 10 min at 10000xg; then the supernatant was transferred into a clean tube. The MMC extraction was repeated with 1 ml of acetonitrile and the second supernatant was added to the first and dried under nitrogen protected from light. The residue was reconstituted with 400 μl of HPLC mobile phase (0.01 M NaH₂PO₄ buffer pH 6.5/acetonitrile, 84:16) and analyzed in HPLC.

_In vitro_ degradation of MMC
MMC at concentrations of 0.8 mg/ml was prepared in 0.9% saline and incubated for up to 60 min at 45°C protected from light. Samples were diluted 2000-fold with mobile phase (0.01 M NaH₂PO₄ buffer pH 6.5/acetonitrile, 84:16) and analyzed in HPLC.

HPLC analysis of MMC
MMC concentration in plasma and in the solution recovered after the two instillation period was determined by isocratic reverse-phase HPLC by a method adapted from Dalton. et al. [24]. The HPLC system consisted of a Shimadzu LC‐10ADvp pump and a Shimadzu SPD‐10Avp UV‐Vis detector set at 365 nm; the analytical column was a Symmetry C18 (250x4.6 mm i.d., particle size 5 μm) equipped with a Symmetry C18 guard column supplied by Waters (Vimodrone, Milan, Italy). The mobile phase consisted of a mixture of 0.01 M NaH₂PO₄ buffer pH 6.5/acetonitrile (84:16 v/v) and was delivered at 0.8 ml/min at room-temperature (20±2 °C). In these conditions, the recovery of MMC was >95%, its retention time was about 8 min and its limit of quantification (LOQ) was 1 ng/ml.
Results

*In vitro* degradation of MMC

Incubation of 0.8 mg/ml MMC in 0.9% saline at 45°C in the dark for 30, 45, or 60 min, resulted in a mean loss of 6.6, 7.6 and 7.9%, respectively. The MMC stability was comparable to previous published data [22].

MMC recovery in the instillation residual solution at the end of instillation

A total of 64 instillations were performed for the 11 enrolled patients (mean of 5.8 instillation for each patient). The volume and pH of the residual bladder contents were similar for the 0-22 and 22-45 min instillation periods. Median volume was 90 ml (range 65-150) and 100 ml (range 85-150), respectively, whereas median pH was 5.66 (range 5.51-5.92) and 5.81 (range 5.70-5.96), respectively.

Median MMC concentration in the instillation residual solution decreases from the initial 0.8 mg/ml to 0.22 mg/ml (range 0.11-0.41) for the 0-22 min instillation period and to 0.38 mg/ml (range 0.18-0.59) for the 22-45 min instillation period; the median % of MMC recovered after instillation was 66.2 (range 38.6-92.3) and 99.6 (range 68.6-136), respectively. These results indicate that the MMC absorption occurs mainly during the 0-22 min instillation period and that the degradation of MMC maintained at 45°C in the bladder was minimal, as indicated by the high recovery after the 22-45 min period.

Plasmatic MMC concentration-time profile

Plasmatic MMC concentration-time profiles were examined in 7 patients during the third cycle, in order to better compare our results with those obtained by Paroni et al. [22] that measured the MMC pharmacokinetics at 21-40 days after TUR. Figure 1 shows the plasma MMC concentration-time profiles for the 7 patients, for patient 3 the analysis was repeated during the fourth cycle as the concentrations measured during the third cycle were abnormally high, probably due to an irritation of the bladder wall. In all patients MMC plasmatic levels were very low, and $C_{max}$ resulted always considerably lower than the reported threshold concentration for toxicity (400 ng/ml), even when the permeability of the bladder wall was increased as occurred in patient 3 ($C_{max} = 142$ ng/ml). The almost negligible passage of MMC through the bladder into the systemic circulation account for the lack of systemic toxicity observed during the treatment for all patients.

Efficacy analysis

The clinical study is still in progress, and the data of efficacy are available for all patients only after 1 year of follow-up. Overall, we observed a recurrence rate of 27.3% (3 of the 11 patients) during the first year.

Safety analysis

During the positioning of the catheter and the execution of procedure, no technical miscarriage was reported for any of the 64 instillations performed. Nine patients completed all the 6 planned cycles, whereas for 2 patients, the treatment was discontinued at the 5th cycle because of an allergic reaction (skin rash, Grade 3). None of the treated patients complained of nausea or vomiting, and no hematological or other systemic toxicity, apart from allergic reaction, was reported, the reported side effects were local and mild ($\leq$ Grade 2) (Table 2). During the endoscopic follow up, we did not observe neither bladder wall necrosis nor heating injuries.
Discussion

The management of patients affected by intermediate-risk TCC, after TUR, represents a still unsolved problem for the urologic oncology, as this type of TCC is characterized by a low risk of progression, but a high risk of recurrence. Endovesical instillation of BCG proved to be the most effective treatment in order to delay or prevent recurrence, but it is associated with a number of local and systemic side effects and a rate of recurrence of about 38% after 2 years post TUR [9,5]. At present, the only remaining therapeutic options for patients that relapse after BCG, is the resection of tumors by repeated TURs (or a radical cystectomy for the worst cases), as intravesical instillation of conventional cytostatic drugs proved to be less effective than BCG in reducing the risk of tumor recurrence [5,3].

In the last twenty years, a number of different alternative strategies have been tested in order to enhance the penetration of the drug into the tumor, with the aim to increase the efficacy of conventional cytostatic drugs. One of the most promising among these strategies is the intravesical instillation of MMC by thermo-chemotherapy, that is able to improve the recurrence-free survival without determining a rising in the local or systemic side effects compared to intravesical chemotherapy alone [18]. Till now, however, each and all the authors that published papers about the application of intravesical thermo-chemotherapy in the treatment of bladder cancer described the use of a microwave generating device, in order to induce intravesical hyperthermia. This device, distributed by Medical Enterprises with the name of Synergo®, is currently already approved by the European Standard Authorities (CE), and it is waiting for approval from the U.S. Food and Drug Administration (FDA). The common clinical application of Synergo® for intravesical thermo-chemotherapy, however, is still limited by the high costs of the necessary equipment and the requirement of expressly trained staff.

In our clinical trial we evaluated, for the first time, the feasibility of the intravesical thermo-chemotherapy performed by UniThermia®, a new alternative experimental system, based on conductive instead of microwave-induced heating. At present, some aspects regarding the enhancement obtained by hyperthermia, the extent of systemic absorption of MMC intravesically administered with different protocols and the efficacy of an early instillation of MMC are still unclear. A number of studies demonstrated that an early instillation of MMC (within 24 hours from TUR) is able to reduce the odds of tumour recurrence and it is safe, but limited information is available in the literature regarding the systemic absorption of MMC [3]. Very recently, Maffezzini et al. demonstrated low peak blood levels of MMC (average 18.5 ng/ml for large transurethral resection of bladder) after a single-dose instillation given immediately after TUR, with low systemic and local toxicity, but the study was performed with MMC alone, without hyperthermia [25]. Dalton et al. compared the systemic MMC pharmacokinetics in patient treated with intravesical MMC (without hyperthermia) at different time since TUR. The results demonstrated higher peak blood levels of MMC (average 43 ng/ml) in patients treated 1-3 days since TUR, compared to patients treated 1 or more weeks later, but MMC plasma levels were, in any case, below the threshold for toxicity [24]. Finally, Paroni et al. compared the plasmatic MMC pharmacokinetics in patients treated 21-40 days after TUR with intravesical MMC with or without hyperthermia, and observed a significative increase in plasmatic MMC C_max in the group treated with hyperthermia compared to the group treated with MMC alone (5.6 vs 1.1 ng/ml respectively, p≤0.001), but for all the patients the levels of MMC were always very low [22].

In this study, 11 patients, affected by intermediate risk TCC and relapsing after TUR and BCG treatment, were treated with 6 cycles of weekly instillation of MMC 40 mg for 45 minutes at 45°C. In our study, we decided to treat the patients with a first cycle 24 hours post TUR in order to benefit from the early instillation, assuming that the plasmatic MMC C_max induced by hyperthermia should be only a little higher than the C_max described in the literature for intravesical MMC alone [24,25]. The total lack of systemic toxicity evidenced in our study by the patients during the first cycle demonstrated that the early instillation is safe even if administered in hyperthermia.

The amount of MMC in the residual bladder content at the end of the instillation period was evaluated, in order to determine the stability and the absorption of drug during the treatment, and, at the same time, the systemic exposure of the patients to the drug was assessed by evaluating the MMC plasmatic pharmacokinetics during hyperthermia treatment. UniThermia® proved to be a safe and easy-to-use system for the delivering of MMC by intravesical thermo-chemotherapy, as no technical miscarriage nor serious side effects was reported. Nine patients completed all the 6 planned cycles, whereas 2 patients missed the last cycle because of an allergic reaction. However, the rate of allergic reaction reported in our study, about 3%, is comparable with the rate reported in the literature for the use of intravesical MMC alone [9]. No other systemic toxicities were observed, the local toxicities were in any case mild.

MMC at concentration of 0.8 mg/ml in 0.9% saline showed a good stability (less than 10% loss) after a 60 min incubation in vitro at 45°C in the dark. This finding was confirmed by the good intravesical MMC stability during the 22-45 min instillation period, with a recovery of 99.6% in the residual bladder content. Despite this stability, our results suggest to maintain a schedule that provides for a replacement of MMC solution after the first 22 minutes of treatment, since the MMC absorption occurs mainly during the first minutes of instillation, as demonstrated by the low amount of recovered MMC (66.2%) at the end of this period. For that reason the replacement of instillation solution is important to assure an optimal intravesical concentration of MMC for the entire duration of the hyperthermia treatment.

The plasmatic MMC concentration during the instillation was always very low and well below the threshold level for myelosuppression, even if the permeability of the bladder wall is increased as a result of an inflammatory condition or the TUR procedure. This finding was well confirmed by the total lack of hematological toxicity evidenced by the patients during the study. The results obtained in our study demonstrate that the MMC stability and systemic absorption during the hyperthermia treatment performed with UniThermia® are comparable with the results described by Paroni et al. with the Synergo® system [17,22].
The use of conductive heating in order to induce intravesical hyperthermia prevents the risk of burns during the treatment, as demonstrated by the total lack of bladder wall necrosis or heating injuries observed in our patients during the endoscopic follow up. However, the temperature of the bladder wall has not been monitored during the procedure, therefore, the efficacy of conductive heating to uniformly increase the temperature across the different layers of bladder wall is still to be demonstrated, as the blood flow could dissipate the heat, especially at submucose and muscle level. Very recently Cordeiro et al. described a novel multisensor probe for monitoring bladder temperature during locoregional thermo-chemotherapy. This probe should be useful in order to resolve this issue [26].

In order to evaluate the efficacy of the treatment performed with UniTherma® in reducing the disease recurrence rate in short- and long term follow-up, we are currently carrying out a clinical multicentric study involving a larger number of patients.

Conflict of interest

None declared.
Figure 1: plasma MMC concentration-time profiles.
Table 1. Clinical and demographic characteristics of the patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Median age (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65 (51-79)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9</td>
</tr>
<tr>
<td>Female</td>
<td>2</td>
</tr>
<tr>
<td>Tumour stage</td>
<td></td>
</tr>
<tr>
<td>Ta</td>
<td>9</td>
</tr>
<tr>
<td>T1</td>
<td>2</td>
</tr>
<tr>
<td>Tumour grade</td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>7</td>
</tr>
<tr>
<td>G2</td>
<td>4</td>
</tr>
<tr>
<td>Recurrences</td>
<td></td>
</tr>
<tr>
<td>≤4</td>
<td>4</td>
</tr>
<tr>
<td>&gt;4</td>
<td>7</td>
</tr>
</tbody>
</table>
Table 2. Occurrence of side effects during the 64 cycles

<table>
<thead>
<tr>
<th>Side Effect</th>
<th>Occurrence</th>
<th>% of cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>No side effects</td>
<td>47</td>
<td>73,4</td>
</tr>
<tr>
<td>Urinary frequency</td>
<td>8</td>
<td>12,5</td>
</tr>
<tr>
<td>Urinary urgency</td>
<td>4</td>
<td>6,3</td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td>1</td>
<td>1,6</td>
</tr>
<tr>
<td>Urethral pain</td>
<td>1</td>
<td>1,6</td>
</tr>
<tr>
<td>Bladder cramping</td>
<td>2</td>
<td>3,1</td>
</tr>
<tr>
<td>Cystitis</td>
<td>6</td>
<td>9,4</td>
</tr>
<tr>
<td>Skin rash</td>
<td>2</td>
<td>3,1</td>
</tr>
</tbody>
</table>
References


